RecruitingPriority 2 · High priorityNCT07311746
Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia
Plain-language summary
This trial is testing Ruxolitinib for patients with T-cell prolymphocytic leukemia (T-PLL) whose disease has come back or stopped responding to prior treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. This trial is available at 1 location in the United States. The trial is currently recruiting patients.
Who can join (key eligibility)
- Age 18 Years or older
- Lymphoma came back or did not respond to prior treatment
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Ruxolitinib (DRUG): Given orally | Cladribine (DRUG): Given by injection | Venetoclax (DRUG): Taken by mouth
Ruxolitinib, Cladribine, Venetoclax
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details